BioCentury
ARTICLE | Finance

More NASH cash

Why investors are backing Cirius’ next-generation insulin sensitizer in NASH

April 14, 2017 8:04 PM UTC

Investors are hoping a $40 million A-2 round can help Cirius Therapeutics Inc. deliver the first clinical data in non-alcoholic steatohepatitis (NASH) showing a second-generation insulin sensitizer is not only efficacious, but also avoids the safety issues of first-generation sensitizers.

Frazier Healthcare Partners and Novo A/S led last week’s round, with participation by fellow new investors Adams Street Partners and Renaissance Venture Capital Fund and existing investor Hopen Life Science Ventures. ...

BCIQ Company Profiles

Cirius Therapeutics Inc.